A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Official title

KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis

Overview

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Interventions

• Biological KB407 (Nebulization)
  Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR

Primary outcome measures

• To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results [Time frame: 6 months]

Secondary outcome measures (1)

• To evaluate the effects of KB407 on pulmonary function, as measured by change from baseline in absolute and percent predicted FEV1 [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

• The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions
• Subjects aged 18 years or older at the time of Informed Consent
• A confirmed diagnosis of CF as defined by clinical signs and symptoms of CF and at least one of the following:

• A historical sweat chloride value >60 mmol/L
• Two copies of a disease causing mutation in the CFTR gene
• Clinically stable in the opinion of the Investigator
• Percent predicted FEV1 ≥40% and ≤90% of the predicted normal for age, gender, and height at Screening
• Resting oxygen saturation ≥92% on room air at Screening

Exclusion criteria

• Initiation of any new chronic therapy (eg, CFTR modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose
• Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the Investigator, may confound study results
• Treatment for Mycobacterium abscessus within 3 months prior to the first dose or more than two pulmonary exacerbations with a history of Burkholderia cenocepacia infection within 6 months prior to the first dose
• Participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose
• History of or listed for solid organ transplantation
• Any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB407
• An active oral herpes infection 30 days prior to the first dose
• Women who are pregnant or nursing
• Subject who is unwilling to comply with contraception requirements per protocol
• Clinically significant abnormalities of hematology or chemistry testing at Screening that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment
• Subject has a known hypersensitivity to inhaled glycerol
• Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
• Bronchoscopy participants only: Unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the Investigator
• Cohort 4 participants only: Subjects who are ineligible for, do not tolerate, or do not benefit from modulator therapy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 6 centers

• University of Florida, Gainesville — Gainesville
• St. Lukes CF Center of Idaho — Boise
• The Cystic Fibrosis Institute — Northfield
• New York Medical College/ Boston Children's Health Physicians — Hawthorne
• Northwell Health Physicians — New York
• Atrium Health Wake Forest Baptist Medical Center — Winston-Salem

Identifiers

NCT: NCT05504837 · KB407-02

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗